Once operational, the Moderna Innovation and Technology Centre (MITC) is intended to provide access to a domestically manufactured portfolio of future mRNA vaccines against respiratory viruses, pending regulatory assessment and licensure. In addition, the facility is intended to provide the UK with direct access to pandemic response capabilities, which will support the UK in its global efforts as part of its “100 Days Mission” to reduce the impact of future pandemics.
Construction is expected to commence in early 2023, with the facility expected to become operational by 2025.